中国卒中杂志2016，Vol.11Issue(6)：462-467,6.DOI:10.3969/j.issn.1673-5765.2016.06.008
急性缺血性卒中3 h内rt-PA溶栓的成本效用分析
Cost-Utility Analysis of rt-PA Thrombolysis within 3 Hours of Acute Ischemic Stroke
摘要
Abstract
Objective To determine the cost-utility of recombinant tissue-type plasminogen activator (rt-PA) treatment within 3 hours after onset of acute ischemic stroke in China. <br> Methods A combination of decision tree and Markov model was developed to determine the cost-utility of rt-PA treatment versus non-rt-PA treatment within 3 hours after stroke onset. Outcomes, costs, utility and transfer proportion of the model were derived from the database and the literatures. Incremental cost-effectiveness ratio (ICER) was estimated in both short term (2 years) and long term (30 years). <br> Results Compared to non-rtPA treatment, rt-PA treatment within 3 hours had ICER of CNY 93,796 per quality-adjusted life-year (QALY) gained in 1 year which was lower than a willingness-to-pay threshold of CNY 105,000 (3 GDP of China) per QALY. Thrombolysis also had an ICER of CNY 5,953 per QALY gained in 30 years which was lower than a willingness-to-pay threshold of CNY 35,100 (1 GDP of China) per QALY. <br> Conclusion Intravenous rt-PA treatment within 3 hours is highly cost-effective for acute ischemic strokes in China.关键词
成本效用分析/成本效果/溶栓/卒中/健康调整寿命年Key words
Cost-utility analysis/Cost-effective/Thrombolysis/Stroke/Quality-adjusted life-year引用本文复制引用
潘岳松,王伊龙,廖晓凌,刘改芬,姜勇,王春娟,张润华,王拥军..急性缺血性卒中3 h内rt-PA溶栓的成本效用分析[J].中国卒中杂志,2016,11(6):462-467,6.基金项目
国家科技支撑计划项目（2013BAI09B03；2006BAI01A11；2011BAI08B01；2011BAI08B02）脑血管病创新药物临床评价技术平台建立（2012ZX09303-005-001)北京脑重大疾病研究院项目（BIBD-PXM2013_014226_07_000084）首都卫生发展科研专项项目（首发2011-2004-05）北京市科技计划重大项目 （）
